𝐁𝐢𝐨𝐕𝐞𝐧𝐭𝐮𝐫𝐞 𝐕𝐨𝐢𝐂𝐞𝐬: Episode 3: Time BioVentures' D.A. Wallach. D.A. Wallach describes how he went from music to healthcare/biotech investing, and the similarities he sees between the two . Plus, the firm's investment philosophy and how he partnered with Timothy Wright to create the firm. Full video: https://lnkd.in/grxX-86a BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
About us
News, stories, and educational videos about the biotechnology sector. Bringing biotech to life. 📺
- Website
-
https://www.biotechtv.com
External link for BiotechTV
- Industry
- Internet News
- Company size
- 2-10 employees
- Headquarters
- Seaport, Boston
- Type
- Privately Held
- Founded
- 2023
- Specialties
- Biotech and News
Locations
-
Primary
Seaport, Boston, US
Employees at BiotechTV
Updates
-
Next week will kick off leg two of the European biotech tour. We’ve got some cool visits planned. Please tune in.✌️
𝐄𝐮𝐫𝐨𝐩𝐞 𝐓𝐨𝐮𝐫: BiotechTV is kicking off a two month tour of Europe this week. Tune in as Brad Loncar speaks with industry leaders and takes you behind the scenes of some of Europe's most innovative companies. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Oxford, UK based Enara Bio announced a $32.5M series B to further its work developing TCR based therapies that target antigens found in the 'dark genome'. President & CEO Kevin Pojasek describes how the company searches for these novel cancer-specific antigens that are from areas of the genome that were previously thought to be non coding. Plus, new investors who have participated in the round and how it will enable to company to pursue its internal programs. Full video: https://lnkd.in/erUFKrps BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐀𝐧𝐚𝐥𝐲𝐬𝐭 𝐓𝐡𝐮𝐫𝐬𝐝𝐚𝐲𝐬: Mizuho senior analyst Graig Suvannavejh, PhD joins BiotechTV for Analyst Thursdays from Kendall Square. He shares his take on biotech and discusses Terns, Novo Nordisk, Corbus, Harmony Bio, IDEAYA, and Adverum. Full video: https://lnkd.in/ggu5GcV3 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐓𝐡𝐞 𝐒𝐭𝐮𝐝𝐢𝐨 𝐚𝐭 𝐊𝐞𝐧𝐝𝐚𝐥𝐥 𝐒𝐪𝐮𝐚𝐫𝐞: Gene therapy experts TJ Cradick, Ph.D. and Kate (Katherine) Excoffon discuss using AAV gene therapy for cystic fibrosis Dr. Excoffon describes her academic experience that led her to the field and Spirovant Sciences, discusses interesting data from last month’s North American Cystic Fibrosis Conference, and then highlights Spirovant Sciences, Inc.'s program and why using a small molecule modulator like doxorubicin might be the key to success. Full video: https://lnkd.in/gaNZSPw4 The Studio at Kendall Square is brought to you by MassBio. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐓𝐚𝐥𝐤𝐢𝐧𝐠 𝐒𝐜𝐢𝐞𝐧𝐜𝐞: Vedanta Biosciences, Inc. founder and CEO Bernat Olle shares an expert take on microbiome drug development. He describes how Vedanta is isolating specific bacterial strains and using them as a defined composition for its medicines, and why he thinks that is important. Plus, lead programs against C. diff and IBD, and where he sees the broader utility for microbiome therapeutics in the future. Full video: https://lnkd.in/gP_7JySc BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐓𝐚𝐥𝐤𝐢𝐧𝐠 𝐒𝐜𝐢𝐞𝐧𝐜𝐞: Flagship's ProFound Therapeutics is searching for proteins for use as therapeutics and targets beyond those found in the traditional protein coding regions of DNA. CEO John Lepore, MD, who was previously head of research at GSK, describes how the company is screening all proteins that are made by ribosomes, and then tests the functionality of novel ones to see if they can be harnessed as therapeutics or new drug targets. Full video: https://lnkd.in/gdqqYVX5 BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Vor Bio is trying to help AML patients who receive a stem cell transplant to be more amenable to follow-on therapies. They just had key PoC data. President and CEO Robert Ang describes how Vor knocks out CD33 in transplant cells before they are administered so that patients can tolerate follow-on treatments like Mylotarg and CAR-T easier and earlier. He describes clinical data the company announced last month. Full video: https://lnkd.in/eHUjqipH BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐁𝐞𝐧𝐜𝐡𝐭𝐚𝐥𝐤: Biotech lab technologies expert Bob Gantzer talks about the digital lab book, rovers, and future technologies still to come in biotech. #Benchtalk The VP of Lab Technologies at Aera Therapeutics describes what lab work was like before technology digitized and dramatically changed everything, and the goal today of building out fully automated and closed systems to work from. Full video: https://lnkd.in/gS2fykTu Today's content is brought to you by Benchling BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
𝐁𝐞𝐧𝐜𝐡𝐭𝐚𝐥𝐤: Mathai Mammen, M.D., Ph.D. provides an update on the latest at FogPharma, and his philosophy of following the cadence of science, not the calendar. #Benchtalk The Chairman and CEO of FogPharma describes the progress the company has made this year, including on the lead β-catenin/TCF4 inhibitor program, and a partnership on an alpha-particle radioligand platform. Plus, leadership advice and how technology has changed science. Full video: https://lnkd.in/gtdwz7KM Today's content is brough to you by Benchling BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent